

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

French 1

Section 1. Identifying Information					
Given Name (First Name) Jacqueline	2. Surname (Last Name) French	3. Effective Date (07-August-2008) 12-July-2011			
4. Are you the corresponding author?	✓ Yes No				
5. Manuscript Title Lamotrigine XR Conversion to Monoti	nerapy: First Study Using a Historical Cont	rol Group			
6. Manuscript Identifying Number (if you I	know it)				

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration :	for Pub	lication			
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**
1. Grant			V	Glaxo Smith-Kline	\$10,000 Syears ago to create a historical control
2. Consulting fee or honorarium				Glaxo Smith-Kline	\$600 consulting fee X
Support for travel to meetings for the study or other purposes				Glaxo-Smith-Kline	Travel to AAN in 2010 to present results of this study
 Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like 	V				×
Payment for writing or reviewing the manuscript	7				ADD X ADD

The Work Under Consideration	for Pub	lication				
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
Provision of writing assistance, medicines, equipment, or administrative support	V					×
7. Other	Ø					ADD × ADD

French

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add \pm " box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
1. Board membership				·		×
2. Consultancy				Glaxo Smith Kline	\$600 for consulting	AD AD
3. Employment	Ø					AC
4. Expert testimony	7					×
5. Grants/grants pending			Ø	Glaxo Smith-Kline	Grant for a photosensitivity study \$30,000	>

^{*}This means money that your institution received for your efforts on this study.

^{**} Use this section to provide any needed explanation.



Relevant financial activities out	side the	submit	ted work			
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
 Payment for lectures including service on speakers bureaus 	Ø					× ADD
7. Payment for manuscript preparation	V					×
8. Patents (planned, pending or issued)	V					ADD X
9. Royalties						ADD X ADD
Payment for development of educational presentations	V					X ADD
11. Stock/stock options	7					X ADD
12. Travel/accommodations/ meeting expenses unrelated to activities listed**						X ADD
13. Other (err on the side of full disclosure)	V					X

^{*}This means money that your institution received for your efforts.

^{**} For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.



Section 4. Other relationships
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No other relationships/conditions/circumstances that present a potential conflict of interest
Yes, the following relationships/conditions/circumstances are present (explain below):
JA French has served on the scientific advisory board of UCB, Johnson & Johnson, Eisai, Novartis, Valeant, Icagen, Intranasal, Sepracor, and Marinus. Dr. French has received funding for travel from UCB, Kyowa, Eisai, Johnson & Johnson, Valeant, and GlaxoSmithKline. She is an associate editor for Epilepsy Currents and the supplements editor for Epileptic Disorders. Dr. French is the president of the Epilepsy Study Consortium that receives money from multiple pharmaceutical companies; 20% of her salary is paid by the consortium. She has received research support from SK, Valeant, Pfizer, UCB, Eisai, Johnson & Johnson, the NIH, and the Epilepsy Research Foundation.
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Mide All Table Rows Checked 'No' SAVE

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.